Omeros
About OmerosPipelineInvestorsNews


2015 Press Releases

E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
11/09/15Omeros Corporation Reports Third Quarter 2015 Financial Results
-- Conference Call Today at 4:30 p.m. ET -- SEATTLE, Nov. 9, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the third quarter of 2015, which in... 
 Printer Friendly Version
11/02/15Omeros Corporation to Announce Third Quarter 2015 Financial Results on November 9, 2015
SEATTLE, Nov. 2, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its third quarter 2015 financial results for the period ended September 30, 2015, on Monday, November 9, 2015, after marke... 
 Printer Friendly Version
10/15/15Omeros Announces OMIDRIAssure™ to Expand Patient Access to Omidria®
-- Ensures Access to Benefits of Omidria for Cataract Patients, Surgeons and Facilities -- SEATTLE, Oct. 15, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has launched OMIDRIAssure™, a comprehensive reimbursement services program to provide expanded access to Omidria® (phenylephrine and ketorolac injection) 1% / 0.3% for cataract surgery patients and reimbursement assistance for physicians and facilities. The program services include the: OMIDRIAssure Inf... 
 Printer Friendly Version
09/03/15Omeros Files Infringement Suits Against Par
SEATTLE, Sept. 3, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed patent infringement lawsuits against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC, (collectively "Par") in the U.S. District Court for the District of New Jersey and in the U.S. District Court for the District of Delaware. The lawsuits were filed under the Hatch-Waxman Act for Par's infringement of three Omeros patents, U.S. Patent Nos. 8,173,707, 8,586,633 and 9,0... 
 Printer Friendly Version
08/18/15Omeros Announces Additional Positive Data in OMS721 Phase 2 Clinical Trial
-- Company Plans for Phase 3 Program Based on Consistent Response in TMA Patients -- SEATTLE, Aug. 18, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body's organs, ... 
 Printer Friendly Version
08/17/15Omeros Announces Plan to File Infringement Suit Against ANDA Filer
SEATTLE, Aug. 17, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today, in response to investor questions, announced that it plans to file a patent infringement lawsuit against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC (Par) in response to the Abbreviated New Drug Application (ANDA) filed by Par seeking FDA approval to market a generic version of Omeros' commercial drug Omidria® (phenylephrine and ketorolac injection) 1%/0.3%. Omidria is approved by the U.S. ... 
 Printer Friendly Version
08/10/15Omeros Corporation Reports Second Quarter 2015 Financial Results
-- Conference Call Today at 4:30 p.m. ET -- SEATTLE, Aug. 10, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the second quarter of 2015, which ... 
 Printer Friendly Version
08/07/15Omeros to Present at the 2015 Wedbush PacGrow Healthcare Conference
SEATTLE, Aug. 7, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2015 Wedbush PacGrow Healthcare Conference in New York next week.  The presentation is scheduled for Tuesday, August 11 at 12:45 pm EDT. The pre... 
 Printer Friendly Version
08/03/15Omidria® Approved for Commercialization Throughout the European Union and Additional Countries
-- Approval by the European Commission Follows Unanimous Recommendation by the EMA -- SEATTLE, Aug. 3, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the European Commission (EC) has granted marketing authorization for Omidria (phenylephrine and ketorolac injection) 1% / 0.3% in the European Union (EU) for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative... 
 Printer Friendly Version
07/31/15Omeros Corporation to Announce Second Quarter 2015 Financial Results on August 10, 2015
SEATTLE, July 31, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its second quarter 2015 financial results for the period ended June 30, 2015, on Monday, August 10, 2015, after market cl... 
 Printer Friendly Version
07/23/15FDA Grants "Fast Track" to Omeros' Complement Inhibitor OMS721 for aHUS
-- Phase 2 Trial and Compassionate Use Program Advance -- SEATTLE, July 23, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to OMS721 for the treatment of patients with atypical hemolytic uremic syndrome (aHUS). OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune sy... 
 Printer Friendly Version
06/17/15Rajiv Shah, M.D., Appointed to Omeros' Board of Directors
SEATTLE, June 17, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that Rajiv Shah, M.D., recent Administrator of the United States Agency for International Development (USAID), has been appointed to serve on the company's board of directors. From 2010 to 2015, Dr. Shah served as Administrator of USAID, the U.S. government agency responsible for administering civilian foreign aid. During his tenure, Dr. Shah led the efforts of nearly 10,000 staff in more than 70 countrie... 
 Printer Friendly Version
06/16/15Omeros Announces Exclusive License Agreement for Omeros' Arthroscopic Product OMS103
-- U.S. Sales to Begin This Year -- SEATTLE, June 16, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications, today announced that it has entered into an exclusive license agreement with affiliates of Fagron NV (EBR: FAGR) for the commercialization of OMS103, Omeros' product for arthroscopic surgery. OMS103, added ... 
 Printer Friendly Version
05/22/15Omidria® Receives Positive Opinion from European Medicines Agency's Committee for Medicinal Products for Human Use
- Unanimous Recommendation to Grant European Marketing Authorization for Omidria Based on Benefit/Risk Profile - SEATTLE, May 22, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the European Medicines Agency... 
 Printer Friendly Version
05/11/15Omeros Corporation Reports First Quarter 2015 Financial Results
-- Omidria Now Widely Available in the U.S. Following Commercial Launch -- SEATTLE, May 11, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the ... 
 Printer Friendly Version
05/05/15Omeros Corporation to Announce First Quarter 2015 Financial Results on May 11, 2015
SEATTLE, May 5, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its first quarter 2015 financial results for the period ended March 31, 2015, on Monday, May 11, 2015, after market close. ... 
 Printer Friendly Version
04/14/15European Regulatory Authority Approves Clinical Investigator's Request for Compassionate Use with Omeros Corporation's OMS721
-- Patients with Thrombotic Microangiopathy Will Now Be Able to Receive Extended Treatment - SEATTLE, April 14, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the presiding European regulatory authority has approved the company's investigational product OMS721 for compassionate use. OMS721 is Omeros' lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of thrombotic microangiopathies ... 
 Printer Friendly Version
04/09/15Omeros to Present at the 14th Annual Needham Healthcare Conference
SEATTLE, April 9, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 14th Annual Needham Healthcare Conference in New York next week... 
 Printer Friendly Version
04/02/15Omeros Corporation Announces the U.S. Commercial Launch of Omidria™
-- First and Only FDA-Approved Intraocular Product that Prevents Pupil Constriction and Reduces Postoperative Pain -- SEATTLE, April 2, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, announced today the nationwide commercial availab... 
 Printer Friendly Version
03/16/15Omeros Corporation Reports Fourth Quarter and Year-End 2014 Financial Results
-- 4Q 2014 net loss of $20.7 million, or $0.61 per share -- SEATTLE, March 16, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the fourth quarter and... 
 Printer Friendly Version
03/09/15Omeros Corporation to Announce Fourth Quarter and Full-Year 2014 Financial Results on March 16, 2015
SEATTLE, March 9, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its fourth quarter and full-year 2014 financial results for the period ended December 31, 2014, on Monday, March 16, 2015, aft... 
 Printer Friendly Version
02/19/15Omeros Corporation's Phase 2 OMS721 Trial Resulting in Extended Access for Compassionate Use
- The Company Agrees to Physician Request to Continue Treatment of Patients with aHUS - SEATTLE, Feb. 19, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has completed dosing of the low-dose cohort of patients in its ongoing Phase 2 clinical trial evaluating the efficacy and safety of OMS721, the lead human monoclonal antibody for its mannan-binding lectin-associated serine protease-2 (MASP-2) program, in treating thrombotic microangiopathies (TMAs). TMAs are a ... 
 Printer Friendly Version
02/03/15Omeros Closes $84 Million Public Offering of Common Stock and Pre-Funded Warrants
SEATTLE, Feb. 3, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has closed the underwritten public offering that was priced and allocated to investors on January 28, 2015 relating to the sale of 3,444,831 shares of its common stock at a price of $20.03 per share and 749,250 pre-funded warrants to purchase up to an equal number of shares of its common stock at a price per warrant of $20.02, which was paid at closing. The pre-funded warrants have an exercise price o... 
 Printer Friendly Version
01/29/15Omeros Prices $75 Million Public Offering of Common Stock and Pre-Funded Warrants
SEATTLE, Jan. 29, 2015 /PRNewswire/ --Omeros Corporation (NASDAQ: OMER) today announced that it has priced an underwritten public offering of 2,995,506 shares of its common stock at a per share price to the public equal to $20.03, and pre-funded warrants to purchase up to 749,250 shares of its common stock, at a per warrant price to the public equal to $20.02.  The pre-funded warrants have a term of seven years and an exercise price of $0.01 per share. Total gross proceeds, including the approxi... 
 Printer Friendly Version
01/28/15Omeros Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SEATTLE, Jan. 28, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced its intention to offer, subject to market and other conditions, shares of its common stock and pre-funded warrants to purchase shares of its common stock in a registered underwritten public offering. The pre-funded warrants shall be offered at the same price per share as the common stock, less the $0.01 per share exercise price of each pre-funded warrant. Omeros also expects to grant the underwriters a 30-da... 
 Printer Friendly Version